• SynAct signed a term sheet with Brazil’s Hipolabor for co-development, licensing, commercialization of resomelagon to treat dengue in Brazil.
• Definitive agreement targeted in coming months; Brazil described as the world’s largest dengue market.
• Commercial deal structure set at 50-50 profit share; additional sales milestones tied to the first USD 200 million accumulated net sales.
• Development costs split 50-50 to support regulatory approval in Brazil.
• SynAct retains full control of resomelagon, preserving flexibility for partnering across other indications and territories.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SynAct Pharma AB published the original content used to generate this news brief on August 19, 2026, and is solely responsible for the information contained therein.